Di Yu

Di Yu

Company: Elicera Therapeutics

Job title: Head of Translational Research


Outlining an iTANK Technology Platform & ELC-201 Promising Therapeutic Efficacy 9:30 am

iTANK is a technology platform that allows us to arm oncolytic virus or CAR-T cells with a pluripotent immunomodulating factor, NAP Elicera’s drug candidate ELC-201 is an iTANK-engineered oncolytic virus further armed to express 4-1BBL ELC-201 exhibits promising therapeutic efficacy against pancreatic cancer in murine model, and induces bystander immune activation by altering the immunosuppressive…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.